Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,015 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
Takahashi N, Kojima T, Terabe K, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. Takahashi N, et al. Mod Rheumatol. 2013 Sep;23(5):904-12. doi: 10.1007/s10165-012-0760-4. Epub 2012 Sep 14. Mod Rheumatol. 2013. PMID: 22975734
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N. Kojima T, et al. Among authors: takahashi n. Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26. Mod Rheumatol. 2013. PMID: 23099471
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.
Hirabara S, Takahashi N, Fukaya N, Miyake H, Yabe Y, Kaneko A, Ito T, Oguchi T, Kida D, Hirano Y, Fujibayashi T, Sugiura F, Hayashi M, Funahashi K, Hanabayashi M, Asai S, Ishiguro N, Kojima T. Hirabara S, et al. Among authors: takahashi n. Clin Rheumatol. 2014 Sep;33(9):1247-54. doi: 10.1007/s10067-014-2711-2. Epub 2014 Jun 28. Clin Rheumatol. 2014. PMID: 24970596 Free PMC article.
Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N. Kobayakawa T, et al. Among authors: takahashi n. Mod Rheumatol. 2015 Mar;25(2):251-6. doi: 10.3109/14397595.2014.953668. Epub 2014 Sep 11. Mod Rheumatol. 2015. PMID: 25211402
Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry.
Fujibayashi T, Takahashi N, Kida D, Kaneko A, Hirano Y, Fukaya N, Yabe Y, Oguchi T, Tsuboi S, Miyake H, Takemoto T, Kawasaki M, Ishiguro N, Kojima T. Fujibayashi T, et al. Among authors: takahashi n. Mod Rheumatol. 2015;25(6):825-30. doi: 10.3109/14397595.2015.1029238. Epub 2015 Apr 30. Mod Rheumatol. 2015. PMID: 25775147
Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Takemoto T, Terabe K, Asai N, Ishiguro N. Takahashi N, et al. J Rheumatol. 2015 May;42(5):786-93. doi: 10.3899/jrheum.141288. Epub 2015 Apr 1. J Rheumatol. 2015. PMID: 25834204
Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
Yoshioka Y, Takahashi N, Kaneko A, Hirano Y, Kanayama Y, Kanda H, Takagi H, Ito T, Kato T, Saito K, Funahashi K, Asai S, Takemoto T, Terabe K, Asai N, Ishiguro N, Kojima T. Yoshioka Y, et al. Among authors: takahashi n. Mod Rheumatol. 2016;26(2):169-74. doi: 10.3109/14397595.2015.1069475. Epub 2015 Aug 19. Mod Rheumatol. 2016. PMID: 26140467
Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Terabe K, Yabe Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Kanayama Y, Oguchi T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. Among authors: takahashi n. J Rheumatol. 2016 Aug;43(8):1475-9. doi: 10.3899/jrheum.151006. Epub 2016 Jun 15. J Rheumatol. 2016. PMID: 27307531
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Oguchi T, Kanayama Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Shioura T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. Among authors: takahashi n. Mod Rheumatol. 2018 Jan;28(1):119-125. doi: 10.1080/14397595.2017.1317320. Epub 2017 May 2. Mod Rheumatol. 2018. PMID: 28463029
6,015 results